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Abstract 
New biological therapies for disabling diseases such as psoriasis may carry both short- and 
long-term risks. Tuberculosis (TB) reactivation is a frequent complication of anti-tumor 
necrosis factor (TNF) therapy. We present 3 cases of psoriasis that were treated with 
different types of anti-TNF and developed TB infection (TBI) during therapy. One of the cases 
was diagnosed as active pulmonary TB and the other 2 cases as latent TBI. All cases received 
appropriate anti-TB treatment, and the anti-TNF therapy was interrupted and then resumed 
according to various clinical considerations. 
 
Introduction 
Tuberculosis (TB) infections (TBI) affect almost one third of the world population. In 
2010, there were about 8.8 million (range 8.5–9.2) incident cases of TB [1]. The 
incidence of TB in Qatar during the last decade remained almost unchanged (43–47 
cases per 100,000 per year) [2], despite two major changes: a threefold increase in the 
population size and the introduction of new immunosuppressing agents, mainly anti-
tumor necrosis factors (TNFs), by various sub-specialties. 
The lifetime incidence of TB in untreated psoriatic patients is unknown. Studies on 
risk factors causing TB did not show that psoriatic patients are at greater risk of 
acquiring TB compared to the general population; however, psoriatic patients are more 
likely to be treated for latent TBI (LTBI) before anti-TNF therapy compared to patients 
with inflammatory bowel disease [3]. Moreover, in one study the in vitro T cell 
responsiveness was diminished towards Mycobacterium tuberculosis in cases with 
severe psoriasis [4].  
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TNF is crucial for immunity against TBI, especially in granuloma formation and in 
maintaining the integrity of granuloma. Before initiation of anti-TNF therapy in 
psoriatic patients, screening for LTBI using the tuberculin skin test (TST), interferon 
gamma release assay (IGRA) and chest X-ray (CXR) revealed a positive reaction in 
about 20% of the cases in the 2009 Swiss study by Laffitte et al. [5]. In a study from 
Greece using TST alone, 50% of the patients showed a positive tuberculin test [3]. In a 
wide-scale study from Italy using IGRA and involving 405 psoriatic patients, 18% of the 
samples showed a positive reaction [6]. 
Complications of biologics are theoretically few, but practically, and with the 
increasing use of those agents, they are no longer rare. Some complications may also be 
fatal or life threatening. Post-marketing surveillance and case reports contribute to 
shedding light on problems that occur in real life, as opposed to in well-designed 
studies done on selected cases or volunteers. Pooling the safety data from studies on 
biologics from different conditions is worthwhile. 
Although screening is effective in the diagnosis of most cases of LTBI prior to anti-
TNF therapy, the risk of developing active TB or LTBI after initiation of therapy is still 
to be considered. All anti-TNF agents have warning labels about the risk of infections, 
namely TB. We present here 3 cases that were sufficiently screened for TBI before 
initiation of anti-TNF treatment and later developed laboratory or clinical signs of 
infection. 
Case Report 
Case 1 
A 47-year-old local male presented with an 8-year history of severe disabling palmoplantar 
psoriasis. He was both hypertensive and diabetic (controlled adult onset). He had no previous history 
of systemic medications and showed low compliance with phototherapy. He was mainly treated with 
local applications of steroids, tar, salicylic acid and calcipotriol. The patient was started on acitretin 
50 mg daily and 50% urea cream with only marginal response after 18 weeks. Due to the severity of 
the condition, the patient was screened before etanercept was added. All tests were within normal 
range, including negative TST and CXR. The patient completed 12 weeks with biweekly 50-mg 
subcutaneous injections, with minor improvement, followed by 12 weeks on once weekly 50 mg 
etanercept without significant change. Both drugs were discontinued and the patient was screened 
again before switching to another anti-TNF; this time IGRA was performed and the result was 
negative. He started adalimumab therapy and showed a good and stable response for 14 weeks until 
he developed fever, night sweating, chills, loss of appetite and persistent cough. The condition evolved 
rapidly, necessitating hospitalization. Bronchial lavage and pleural effusion tabbing of the right lung 
were both positive for TB by polymerase chain reaction. Anti-TB therapy was started and adalimumab 
was discontinued. Six weeks later, the chest condition showed marked improvement, while 
palmoplantar psoriasis worsened and the patient’s ability to walk was limited. Based on the 
recommendation of the pulmonologist and the patient’s consent, adalimumab was resumed on the 
condition of strict compliance with anti-TB therapy and close follow-up by the medical staff. The 
patient was followed up for 26 weeks, with complete clearance of both his chest condition and 
palmoplantar psoriasis. Follow-up of the patient will continue in order to rule out recurrence of TB. 
Case 2 
A 38-year-old local male presented with a 23-year history of generalized plaque psoriasis. His BMI 
was 42, with a physician global assessment (PGA) of 4. He suffered from joint pain in both small and 
large joints, with no radiological findings. He had a positive family history but no history of systemic 
medications. The patient was screened before administration of infliximab therapy. All tests were 
within normal range, including IGRA and CXR. Infliximab was initiated with good response and a 
cessation of joint pain. No side effects were noted in the first year of therapy. During his annual  
Case Rep Dermatol 2012;4:41–46 
DOI: 10.1159/000337145 
Published online: 
February 25, 2012 
© 2012 S. Karger AG, Basel 
ISSN 1662–6567 
www.karger.com/cde 
 
 
 
43 
checkup, an IGRA showed a positive conversion though CXR and microbiology for TB were negative; 
the patient was asymptomatic. LTBI was diagnosed by the pulmonologist and anti-TB treatment was 
started, with a 1-month cessation of infliximab therapy. The patient was followed up for another year; 
his condition is stable, with a continued response to infliximab and no side effects. Follow-up of the 
patient will continue in order to rule out recurrence of TB. 
Case 3 
A 33-year-old local male presented with generalized psoriasis of PGA 3. He is the younger brother 
of case 2, however, with a less severe condition, lower BMI and no associated comorbidities. He was 
treated with short, irregular courses of narrow-band UVB due to poor compliance and no history of 
systemic therapy. The patient was screened before administration of etanercept injection. All tests 
were within normal limits, including IGRA and CXR. The patient showed good response to therapy; 
during his annual checkup he also showed a positive conversion of IGRA, while CXR and microbiology 
were negative for TB. He was referred to a pulmonologist who diagnosed the case similarly as LTBI. 
Anti-TB therapy was given, with a 1-month cessation of etanercept. The patient was followed up for 8 
months, with continued efficacy of resumed etanercept injections and no report of side effects. 
Follow-up of the patient will continue in order to rule out recurrence of TB (table 1). 
Discussion 
The complications of immunosuppression of biologics, particularly the anti-TNFs, 
can be placed into 3 main categories: infections, malignancies and miscellaneous. 
Infections are more frequent and evolve rapidly in short time spans compared to 
malignancies. Since TBI is highly prevalent worldwide, special care is required for the 
screening and monitoring for LTBI in patients on anti-TNF therapy. Most of the current 
guidelines recommend TST as the main screening tool for LTBI in psoriasis patients 
before anti-TNF-α therapy; however, the European S3-guidelines are more flexible and 
suggest the use of either TST or IGRA or both [7, 8]. There are few post-marketing 
reports on the development of both active TB and LTBI after initiation of anti-TNF 
therapy in psoriatic patients [9–11]. Patients may develop serious, life-threatening, 
active TBI quite rapidly and without clinical or investigative predictors. 
Screening for LTBI before treatment with anti-TNF agents in psoriasis patients 
showed varying results [3, 5, 6]. The frequency of LTBI in patients with psoriasis after 
initiation of anti-TNF therapy is also variable across different studies [9–11]. In a 
Spanish study of 144 patients on the 3 anti-TNF agents, 29% showed TST and reTST 
conversion after different periods of therapy [9]. In a study from Taiwan done on 147 
patients using etanercept, adalimumab or both, 11% showed conversion of IGRA after a 
median period of 24 weeks of exposure [10]. Also, in an Italian study done on 50 
patients using the 3 anti-TNFs as monotherapy or combined with methotrexate, 7 
(14%) showed IGRA conversion after 1 year [11]. In this study, 2 cases of IGRA 
conversion were discovered during an annual checkup of anti-TNF therapy 
maintenance and 1 case was diagnosed as active pulmonary TB 10 months after 
starting biologics. 
All types of anti-TNF agents caused TB reactivation in these studies, regardless of a 
higher likelihood of causing LTBI or the duration of therapy. Our study is also in 
agreement with these studies, as it showed that the 3 approved anti-TNFs indicated for 
the therapy of psoriasis, namely infliximab, adalimumab and etanercept, can all 
reactivate TB in psoriatic patients in the relatively short period of time of less than or 
equal to 1 year.  
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The switching of anti-TNFs has thus far not been proved to increase the risk to 
patients to acquire TB, but we have to emphasize that case 1 in this study switched 
from etanercept to adalimumab and we could not ascertain if adalimumab alone was 
responsible for the reactivation of TB, or the prolonged cumulative effect of both drugs 
was the reason. 
In this study, the patients did not receive any other immunosuppressants such as 
methotrexate or cyclosporine before or during therapy. They were all BCG vaccinated 
in their infancy. Except for the first case who was diabetic and the third case who had 
short, interrupted phototherapy sessions, the patients had no other causes of 
immunosuppression or risk factors for TBI. We can conclude that anti-TNF therapy was 
the main risk factor in developing TBI. 
Due to possible false interpretation of the TST, especially in cases of 
immunosuppression, BCG-vaccinated patients and patients who have already started 
anti-TNF therapy, IGRA may have an advantage over TST in both sensitivity and 
specificity [11, 12]. We retested our patients using IGRA and we suggest that, according 
to this study, it is better to retest patients after the first 6 months, and later annually. 
One point of argument is that we were obliged to resume adalimumab in case 1 only 
6 weeks after the start of a full course of multiple-drug therapy for TB. One of the 
comprehensive guidelines [13] stated that it is still debatable whether the anti-TNF 
agent can be restarted before receiving a full course of anti-TB treatment. Thus, 
whether to restart the anti-TNF agent within the time period ranging from a minimum 
of 6 weeks, the time course for a positive smear to turn negative, up to the standard of 9 
months might be mainly a clinical decision. Re-initiation is case dependent and has 
many clinical considerations, such as the extent of TB disease and whether there are 
complications of TB that need special medical or surgical intervention. Other factors to 
be considered are that patient compliance and adherence to therapy is mandatory, as is 
acquiring a non-drug-resistant strain by culture and, lastly, having TB smears which 
have turned negative. However, ideally, a full 9 months of TB therapy is recommended 
before restarting anti-TNF therapy again. 
One last point we should raise here is that rare cases which were initially diagnosed 
as LTBI, and having already received anti-TB therapy before the start of anti-TNF 
treatment, still developed active lymph node TB later [9]. Nevertheless, patients 
diagnosed and treated with active TB may develop recurrence due to drug resistance, 
which adds more responsibility and attention in monitoring these cases. Follow-up of 
our patients will continue in order to rule out the possibility of TB recurrence. 
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Table 1. Clinical and laboratory data of the 3 cases 
                  Case 1  Case 2  Case 3 
                Age, years  47  38  33 
Sex  male  male  male 
BMI  30  42  36 
Duration of psoriasis, years  8  23  15 
Special areas  palms and soles  scalp and flexures  scalp 
Psoriatic arthritis (joint)  no  yes  no 
Psoriasis PGA  3  4  3 
Comorbidity  diabetes and hypertension  massive obesity  obesity 
Family history  negative  positive  positive 
BCG vaccination 
HIV status  
positive 
negative 
positive 
negative 
positive 
negative  
Initial tests for TB 
TST 
IGRA 
CXR 
 
negative 
negative 
negative 
 
not done 
negative 
negative 
 
not done 
negative 
negative 
Post-therapy tests for TB 
IGRA 
CXR 
Microbiology for TB 
 
positive 
positive 
positive 
 
positive 
negative 
negative 
 
positive 
negative 
negative 
Diagnosis of TB status  active TB  LTBI  LTBI 
Anti-TNF therapy 
name and duration 
first, etanercept 6 months 
second, adalimumab 4 months 
infliximab 1 year  etanercept 1 year 
Onset of TB after anti-TNF therapy   10 months  1 year  1 year 
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